Market Cap 142.51B
Revenue (ttm) 16.75B
Net Income (ttm) 1.85B
EPS (ttm) N/A
PE Ratio 32.57
Forward PE 31.66
Profit Margin 11.07%
Debt to Equity Ratio 0.49
Volume 2,079,600
Avg Vol 9,293,395
Day's Range N/A - N/A
Shares Out 1.48B
Stochastic %K 83%
Beta 0.67
Analysts Strong Sell
Price Target $126.90

Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates in two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes, as well as endoluminal sur...

Industry: Medical Devices
Sector: Healthcare
Phone: 508 683 4000
Address:
300 Boston Scientific Way, Marlborough, United States
BillionerOfKing
BillionerOfKing Dec. 25 at 11:28 PM
$BSX Current Stock Price: $95.92 Contracts to trade: $95 BSX Dec 26 2025 Call Entry: $1.40 Exit: $2.36 ROI: 69% Hold ~21 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 25 at 1:25 PM
Actionable Trade Alert for $BSX: Market Context: $BSX is currently trading at $96.13, positioned between its 60-day high of $105.65 and low of $90.42. The RSI at 43.95 indicates a neutral to slightly bearish sentiment, suggesting potential for upward movement if buying pressure increases. Directional Bias: The stock is below its 30-day (97.41) and 50-day (98.57) moving averages, indicating a bearish trend. However, the proximity to the 60-day low may present a buying opportunity if momentum shifts. Trade Plan: - Suggested Entry: $95.50 (slightly below current price to capture potential bounce) - Stop Loss: $93.50 (2.1 ATR below entry) - Take Profit Targets: 1. $100.00 (4.9% gain) 2. $103.00 (7.8% gain) 3. $112.00 (17.5% gain) This plan allows for a risk-reward ratio that supports a potential 17% ROI on target 3 while managing risk effectively. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
TalkMarkets
TalkMarkets Dec. 24 at 8:41 PM
Consumer Sentiment Crashes To 20-Year Low $BSX $NEE $SPY $MDLZ https://talkmarkets.com/content/us-markets/consumer-sentiment-crashes-o-20-year-low?post=546636
0 · Reply
Neahrain8
Neahrain8 Dec. 24 at 4:56 PM
0 · Reply
Risk2Drifter
Risk2Drifter Dec. 24 at 4:34 PM
$BSX medtech leader trending clean on pullbacks
0 · Reply
MegaCapMogul
MegaCapMogul Dec. 24 at 3:55 PM
$BSX Structural upside remains conditional on discipline in balancing growth ambition with capital efficiency, with outcomes shaped by timing and discipline. Market patience is not unlimited.
0 · Reply
ZacksResearch
ZacksResearch Dec. 24 at 2:03 PM
$BSX: Is it still time to buy after a 5.5% climb? 📈 🔍 Shares outpace industry with a 5.5% rise over the past year, trading at a forward P/E of 27.90, above its median and industry average. 📊 Earnings estimates trending upward, backed by a Zacks Rank #2 (Buy). See what makes the investment case strong for BSX 👉 https://www.zacks.com/stock/news/2808432/how-well-is-boston-scientific-placed-for-long-term-endoscopy-growth?cid=sm-stocktwits-2-2808432-body-26163&ADID=SYND_STOCKTWITS_TWEET_2_2808432_BODY_26163
0 · Reply
ZacksResearch
ZacksResearch Dec. 24 at 12:44 PM
$BSX is quietly aiming at a massive growth lane — and most aren’t paying attention. 👀 The Endoscopy unit is targeting an $8B market across pancreaticobiliary, surgery, and obesity, with explicit plans to outgrow the broader market. That’s an aggressive growth ambition baked right into the strategy. See how this expansion plan could move the needle 👉 https://www.zacks.com/stock/news/2808432/how-well-is-boston-scientific-placed-for-long-term-endoscopy-growth?cid=sm-stocktwits-2-2808432-teaser-26125&ADID=SYND_STOCKTWITS_TWEET_2_2808432_TEASER_26125
0 · Reply
BlackNYellow
BlackNYellow Dec. 24 at 11:45 AM
$OMER $BSX PM Halt News Pending
0 · Reply
AmbroLynx
AmbroLynx Dec. 23 at 4:31 PM
$BSX defensive growth, if it holds support and breaks higher that’s trend confirmation with liquidity
0 · Reply
Latest News on BSX
Boston Scientific announces results for third quarter 2025

Oct 22, 2025, 6:30 AM EDT - 2 months ago

Boston Scientific announces results for third quarter 2025


Boston Scientific buys Nalu Medical for $533 million

Oct 17, 2025, 7:09 AM EDT - 2 months ago

Boston Scientific buys Nalu Medical for $533 million


9 Stocks to Buy Before Their Earnings Reports

Oct 13, 2025, 2:53 PM EDT - 2 months ago

9 Stocks to Buy Before Their Earnings Reports

ADBE CSCO GM OKTA ZM


4 Top AI-Powered Healthcare Stocks

Oct 9, 2025, 5:00 AM EDT - 2 months ago

4 Top AI-Powered Healthcare Stocks

OPRX VEEV ZEPP


Top 3 Health Care Stocks That May Explode In September

Sep 19, 2025, 7:01 AM EDT - 3 months ago

Top 3 Health Care Stocks That May Explode In September

ATYR RVPH


Boston Scientific Corporation Is Expensive But Worth It

Aug 9, 2025, 8:53 AM EDT - 4 months ago

Boston Scientific Corporation Is Expensive But Worth It


Cramer's Stop Trading: Boston Scientific

Jul 23, 2025, 10:46 AM EDT - 5 months ago

Cramer's Stop Trading: Boston Scientific


Boston Scientific announces results for second quarter 2025

Jul 23, 2025, 6:30 AM EDT - 5 months ago

Boston Scientific announces results for second quarter 2025


What's Happening With Boston Scientific Stock?

Jun 16, 2025, 11:00 AM EDT - 6 months ago

What's Happening With Boston Scientific Stock?


3 Growth Stocks That Aren't the Magnificent 7

Jun 6, 2025, 2:42 PM EDT - 7 months ago

3 Growth Stocks That Aren't the Magnificent 7

CYBR


Boston Scientific announces results for first quarter 2025

Apr 23, 2025, 6:30 AM EDT - 8 months ago

Boston Scientific announces results for first quarter 2025


BillionerOfKing
BillionerOfKing Dec. 25 at 11:28 PM
$BSX Current Stock Price: $95.92 Contracts to trade: $95 BSX Dec 26 2025 Call Entry: $1.40 Exit: $2.36 ROI: 69% Hold ~21 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 25 at 1:25 PM
Actionable Trade Alert for $BSX: Market Context: $BSX is currently trading at $96.13, positioned between its 60-day high of $105.65 and low of $90.42. The RSI at 43.95 indicates a neutral to slightly bearish sentiment, suggesting potential for upward movement if buying pressure increases. Directional Bias: The stock is below its 30-day (97.41) and 50-day (98.57) moving averages, indicating a bearish trend. However, the proximity to the 60-day low may present a buying opportunity if momentum shifts. Trade Plan: - Suggested Entry: $95.50 (slightly below current price to capture potential bounce) - Stop Loss: $93.50 (2.1 ATR below entry) - Take Profit Targets: 1. $100.00 (4.9% gain) 2. $103.00 (7.8% gain) 3. $112.00 (17.5% gain) This plan allows for a risk-reward ratio that supports a potential 17% ROI on target 3 while managing risk effectively. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
TalkMarkets
TalkMarkets Dec. 24 at 8:41 PM
Consumer Sentiment Crashes To 20-Year Low $BSX $NEE $SPY $MDLZ https://talkmarkets.com/content/us-markets/consumer-sentiment-crashes-o-20-year-low?post=546636
0 · Reply
Neahrain8
Neahrain8 Dec. 24 at 4:56 PM
0 · Reply
Risk2Drifter
Risk2Drifter Dec. 24 at 4:34 PM
$BSX medtech leader trending clean on pullbacks
0 · Reply
MegaCapMogul
MegaCapMogul Dec. 24 at 3:55 PM
$BSX Structural upside remains conditional on discipline in balancing growth ambition with capital efficiency, with outcomes shaped by timing and discipline. Market patience is not unlimited.
0 · Reply
ZacksResearch
ZacksResearch Dec. 24 at 2:03 PM
$BSX: Is it still time to buy after a 5.5% climb? 📈 🔍 Shares outpace industry with a 5.5% rise over the past year, trading at a forward P/E of 27.90, above its median and industry average. 📊 Earnings estimates trending upward, backed by a Zacks Rank #2 (Buy). See what makes the investment case strong for BSX 👉 https://www.zacks.com/stock/news/2808432/how-well-is-boston-scientific-placed-for-long-term-endoscopy-growth?cid=sm-stocktwits-2-2808432-body-26163&ADID=SYND_STOCKTWITS_TWEET_2_2808432_BODY_26163
0 · Reply
ZacksResearch
ZacksResearch Dec. 24 at 12:44 PM
$BSX is quietly aiming at a massive growth lane — and most aren’t paying attention. 👀 The Endoscopy unit is targeting an $8B market across pancreaticobiliary, surgery, and obesity, with explicit plans to outgrow the broader market. That’s an aggressive growth ambition baked right into the strategy. See how this expansion plan could move the needle 👉 https://www.zacks.com/stock/news/2808432/how-well-is-boston-scientific-placed-for-long-term-endoscopy-growth?cid=sm-stocktwits-2-2808432-teaser-26125&ADID=SYND_STOCKTWITS_TWEET_2_2808432_TEASER_26125
0 · Reply
BlackNYellow
BlackNYellow Dec. 24 at 11:45 AM
$OMER $BSX PM Halt News Pending
0 · Reply
AmbroLynx
AmbroLynx Dec. 23 at 4:31 PM
$BSX defensive growth, if it holds support and breaks higher that’s trend confirmation with liquidity
0 · Reply
ZacksResearch
ZacksResearch Dec. 23 at 12:21 PM
$BSX’s premium valuation — justified or a red flag? 🤔 Boston Scientific trades at a 27.77X P/E, above its industry peers ABT and MDT, yet its innovative moves across MedSurg, WATCHMAN, and EP are driving growth. 📈 The stock holds a Zacks Rank #3 with positive earnings estimates for 2025 and 2026. Discover the full analysis here 👉 https://www.zacks.com/stock/news/2807741/should-you-hold-on-to-bsx-stock-despite-its-premium-valuation?cid=sm-stocktwits-2-2807741-body-25905&ADID=SYND_STOCKTWITS_TWEET_2_2807741_BODY_25905
0 · Reply
ZacksResearch
ZacksResearch Dec. 23 at 11:21 AM
$BSX at a premium — conviction play or risk trap? 🤔 The debate is all about valuation right now, with the stock trading at a premium and investors weighing whether holding on still makes sense at these levels. Is BSX worth sticking with at this price? Full breakdown here 👉 https://www.zacks.com/stock/news/2807741/should-you-hold-on-to-bsx-stock-despite-its-premium-valuation?cid=sm-stocktwits-2-2807741-teaser-25904&ADID=SYND_STOCKTWITS_TWEET_2_2807741_TEASER_25904
0 · Reply
RunnerSignals
RunnerSignals Dec. 22 at 8:52 PM
$AMD $BSX $CCL $CDNS $CMI all getting love today! Who's hopping on the upgrade train first? https://stocksrunner.com/news/2025-12-22-stock-upgrades-today-highlight-top-picks
0 · Reply
SPYmyQQQ
SPYmyQQQ Dec. 22 at 3:03 PM
🚀 New Signal ✅ 🏛️ $BSX 🗓️ Dec 22, 2025 💵 Entry: $95.38 🎯 Target (Opt.): $97.67 (+2.40%) 👉 FREE TRIAL! spymyqqq/join/
0 · Reply
1iquid
1iquid Dec. 22 at 8:29 AM
💎 Liquid® Live Actionable Trade Asset: $BSX Contracts: $BSX January 15, 2027 $98 Calls Scale in: $10.71- $13.08 Scale out: $41.63-$71.37 Profit Potential : 430% ROI Blended Join 💎 Here: https://1iquid.com
0 · Reply
IcePhoenix
IcePhoenix Dec. 21 at 8:13 PM
$BSX nasty dip
0 · Reply
OnlyFibs
OnlyFibs Dec. 21 at 5:40 AM
$BSX is at the most critical junction of 2025. 🕵️‍♂️ Technically, we’ve successfully defended the $92 Demand Zone, and the technical 'buy signal' is now active. Watch the $97.85 Supply wall—it’s the gatekeeper for the next 20% move. With UBS reiterating a $140 target and organic sales growing at 15%, the fundamentals are screaming 'undervalued.' 📉💎 I’m looking for a high-volume breakout to confirm the reversal. Stay disciplined. #hovdid
0 · Reply
1iquid
1iquid Dec. 20 at 7:36 AM
OptionWizards Tip (education only): Check a stock’s news flow before trading options on GEV, DHR, or BSX to avoid surprises from unexpected headlines. $GEV $DHR $BSX Not financial advice.
0 · Reply
SmartOptionsAlert
SmartOptionsAlert Dec. 19 at 8:57 PM
Hedge Alert Live - Protect Your Portfolio Contract: $BSX $96.00 Put · DEC 26, 2025 Exp Entry Price: $1.30 - $1.37 Exit Price Target: $1.99 Profit Margin: +53% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 19 at 3:19 PM
Actionable Trade Alert for $BSX: Market Context: $BSX closed at $96.11, currently trading below its 30-day (MA30 = 98.02) and 50-day (MA50 = 98.57) moving averages, indicating a bearish trend. The RSI at 32.14 suggests that the stock is oversold, which may signal a potential reversal. Directional Bias: Given the oversold RSI and proximity to the 60-day low of $90.42, there's a likelihood for a bounce back towards the higher end of its recent range. Trade Plan: - Suggested Entry: $96.50 (slightly above the last close to confirm upward momentum) - Stop Loss: $94.00 (below recent support) - Take Profit Targets: 1. $100.00 (approx. 3.9% gain) 2. $102.50 (approx. 6.8% gain) 3. $112.00 (approx. 16.5% gain, achieving over 17% ROI) This plan positions for a potential recovery while managing risk effectively. https://privateprofiteers.com
0 · Reply
fever69
fever69 Dec. 19 at 9:38 AM
0 · Reply
RunnerSignals
RunnerSignals Dec. 18 at 10:38 PM
Stock Upgrades Today $ARGX $ASTS $ATAI $AUR $BSX biotech space tech autonomous vehicles also making waves in the upgrade buzz https://stocksrunner.com/news/2025-12-18-stock-upgrades-today-highlight-top-picks
0 · Reply